A5104666966- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Bioactive Compounds and Antitumor Agents
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Pain Management and Opioid Use
- Advanced Breast Cancer Therapies
- Esophageal Cancer Research and Treatment
- Viral-associated cancers and disorders
- Palliative Care and End-of-Life Issues
- Genetic factors in colorectal cancer
- Chronic Lymphocytic Leukemia Research
- Neuroblastoma Research and Treatments
- Pharmacological Effects and Toxicity Studies
- Gastrointestinal Tumor Research and Treatment
- Gastric Cancer Management and Outcomes
- Breast Cancer Treatment Studies
- Chemotherapy-induced cardiotoxicity and mitigation
- Radiopharmaceutical Chemistry and Applications
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
Comprehensive Cancer Centers of Nevada
2015-2019
University of Nevada, Las Vegas
2018-2019
University of Nevada, Reno
2016-2017
McKesson (United States)
2016-2017
The US Oncology Network
2016-2017
The University of Texas MD Anderson Cancer Center
2005-2009
University of California, Los Angeles
2005
The University of Texas at Austin
2005
Yale New Haven Hospital
2003
Introduction: Despite a clinically relevant, statistically significant survival benefit with nab -paclitaxel plus gemcitabine and FOLFIRINOX vs single-agent for metastatic pancreatic cancer (mPC), little is known regarding their real-world effectiveness. We analyzed patients mPC using nationally representative electronic medical records database to address this unmet need. Methods: This retrospective analysis of the Navigating Cancer compared outcomes among who received first-line...
Abstract Background: Metastatic triple-negative breast cancer (TNBC) is associated with a poor prognosis and has no targeted therapy options. Programmed death-ligand 1 (PD-L1) expression more prevalent in TNBC than other subtypes. PD-L1 may protect cells from immune-mediated destruction by binding to its receptors PD-1 B7.1. MPDL3280A, human anti-PD-L1 monoclonal antibody an engineered Fc-domain designed for optimized efficacy safety, blocks activity restores tumor-specific T-cell immunity....
14151 Background: Pancreatic cancer is virtually always lethal, and the only FDA-approved therapies- gemcitabine erlotinib- produce objective responses in less than 10% of patients. Curcumin (diferuloyl methane) a plant- derived compound that inhibits nuclear factor-kappa B (NF-kappa B) transcription factor (central to pancreatic growth) has substantial antitumor activity preclinical models. We evaluated toxicity anti-tumor curcumin, its impact on survival biologic correlates. Methods:...
Background: Real-world analyses of treatments for patients with metastatic breast cancer are limited. We evaluated the comparative effectiveness nab -paclitaxel vs. paclitaxel in using data from an electronic medical record database community practices across USA. Methods: performed a retrospective cohort study fully de-identified independent US platform initiating single-agent or as first- second-line treatment December 1, 2010 to October 6, 2014. The clinical efficacy objectives were time...
439 Background: Poor outcome in pancreatic cancer (PDA) is associated partly with stromal hyaluronan (HA) accumulation, which compromises chemotherapy perfusion. PEGPH20, PEGylated recombinant human hyaluronidase, potentiates by depleting HA tumors. Methods: In an ongoing, phase II, open-label, randomized study of PEGPH20+nab-paclitaxel (Nab)+Gemcitabine (Gem) (PAG) vs Nab+Gem (AG) previously untreated stage IV PDA, pts receive PEGPH20 3 µg/kg twice weekly (C1), then (C2+) standard AG...
Abstract BACKGROUND: Meticulous selection of patients for esophageal cancer surgery is critical, because major surgical intervention can cause considerable consequences. For this study, the authors explored their institution's large experience to examine impact age on long‐term patient survival and complications. METHOD: Six hundred consecutive with who underwent (409 received preoperative therapy, 191 first) were analyzed. All demographic information (including American Society...
196 Background: Cancer stemness is thought to be associated with resistance chemotherapies. BBI608, a first-in-class cancer inhibitor that works through inhibiting the Stat3 pathway, has shown potent synergistic anti-tumor activity paclitaxel in vivo. In phase Ib dose escalation study patients advanced solid tumors, BBI608 plus weekly was well tolerated and RP2D of 480 mg BID determined. Methods: Patients heavily pretreated metastatic pancreatic adenocarcinoma were enrolled Ib/II extension...
1094 Background: Napabucasin (BBI-608, BB608) is a first-in-class cancer stemness inhibitor that targets the STAT3 pathway has shown potent synergistic preclinical anti-tumor activity with paclitaxel. In phase Ib dose escalation study in patients (pts) advanced solid tumors, BB608 plus weekly paclitaxel was well tolerated. Methods: Pts metastatic triple negative breast (TNBC) who progressed on prior systemic therapy (including taxanes) were enrolled to assess safety, tolerability, and...
A 74-year-old woman with a history of stage IIIb non-small cell lung carcinoma undergoing concomitant chemoradiation therapy presented to the emergency centre 2-day dyspnea and chest tightness. The patient had pulmonary embolism 1 month earlier, because which she was receiving therapeutic dosage coumadin. On physical examination, …
5578 Background: Napabucasin (BBI-608, BB608) is a first-in-class cancer stemness inhibitor targeting the STAT3 pathway that has shown potent synergistic anti-tumor activity with paclitaxel in vivo. In dose escalation study, BB608 plus weekly was well tolerated patients (pts) advanced solid tumors. RP2D expansion included accrual of pts platinum resistant ovarian (PROC). Methods: Pts epithelial ovarian, fallopian, or peritoneal who have progressed on prior taxane-based regimen and were...
13050 Background: Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) is an oral cationic azaspirane that suppresses angiogenesis by inhibiting both bFGF and VEGF induced proliferation migration. has been shown to down-regulate multiple growth factors involved in tumor progressions metastases, including IL-6, TNF-α, VEGF. Methods: This ongoing, single-center, open-label, ascending dose (modified Fibonacci) Phase I trial of atiprimod patients with advanced cancers (3+3...
1084 Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription and spherogenesis of stem cells (Li et al PNAS 112 (6):1839, 2015). has shown potent synergistic preclinical anti-tumor activity with paclitaxel (PTX). In phase Ib dose escalation study in patients (pts) advanced solid tumors, plus weekly was well tolerated. A II expansion cohort opened for pts previously treated metastatic breast (MBC). Methods:...
618 Background: The treatment of GI carcinomas (CA) is influenced by the presence or absence prognostic and predictive genomic alterations (GA). Tissue sampling historical platform for biomarker assessment, but non-invasive ctDNA assay provides an alternative when tissue unavailable cannot be safely obtained. Methods: Hybrid-capture based profiling using a (FoundationACT) was performed on blood samples from 82 consecutive pts with lower alimentary canal CA. Results: Median age 62 (range...
8524 Background: There is limited information about the characteristics and outcomes of inpatient palliative care consults in cancer centers. Two mobile teams (MT) each with a physician, fellow, nurse, provide consultation to hospitalized patients (pts) complex symptoms. Methods: We analyzed pts during two-month period. The charts were reviewed for demographics, data, reason consultation, symptoms, interventions, outcomes. Results: Sixty-one analyzed. Pain was main consult request 46 (75%),...